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TBM is the most severe form of tuberculosis. Clinical trial data are 
required to provide an evidence base for adjunctive dexamethasone 
in HIV-positive individuals with TBM, and to guide clinical practice. This 
document details the planned analyses at 12 months post 
randomisation for the ACT HIV clinical trial (NCT03092817); ‘a 
randomised double-blind placebo-controlled trial of adjunctive 
dexamethasone for the treatment of HIV co-infected adults with 
tuberculous meningitis (TBM)’. The primary endpoint of the ACT HIV 
trial is death (from any cause) over the first 12 months after 
randomisation. This statistical analysis plan expands upon and 
updates the analysis plan outlined in the published study protocol.
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Scope of document
This document details the planned analyses at 12 months post 
randomisation for the ACT HIV clinical trial (NCT03092817); 
‘a randomised double-blind placebo-controlled trial of 
adjunctive dexamethasone for the treatment of HIV co-infected 
adults with tuberculous meningitis (TBM)’. A further analy-
sis will follow at 24 months post randomisation. This statisti-
cal analysis plan expands upon and updates the analysis plan 
outlined in the published study protocol1.
Background and rationale for study
The ACT HIV clinical trial is a randomised double-blind 
placebo-controlled trial of adjunctive dexamethasone for the treat-
ment of tuberculous meningitis (TBM) in HIV-positive adults. 
TBM is the most severe form of tuberculosis, with mortality 
approaching 50% in people living with HIV2–5 despite 
the best available appropriate anti-TB chemotherapy.
TBM develops when Mycobacterium tuberculosis, initially 
acquired via the respiratory route, disseminates via the blood to 
form a secondary focus in the brain. Rupture of this second-
ary focus into the subarachnoid space results in TBM, with 
the consequent host inflammatory response being important 
for bacterial killing, but also responsible for the pathological 
complications and often-fatal consequences of the infection.
Adjunctive anti-inflammatory corticosteroid therapy, which 
may control excessive host inflammation, has long been con-
sidered to have a role in TBM treatment6. In 2004, a landmark 
clinical trial in Vietnam demonstrated that a 6–8 week (dura-
tion dependent on Modified Research Council [MRC] TBM 
severity grade) tapering course of dexamethasone reduced 
mortality in adults and adolescents with TBM4. In this 
study, only 98/545 (18.0%) individuals were HIV positive, which 
was too small to determine if dexamethasone benefited this 
important sub-group of patients. No other trials have been pub-
lished since 2004 that examine whether corticosteroids improve 
outcomes from TBM in HIV-positive adults.
How dexamethasone might confer its clinical benefit on 
those with TBM remains uncertain. A recent study of cer-
ebrospinal fluid (CSF) cytokines in TBM suggested that HIV- 
positive individuals have higher cytokine concentrations than 
HIV-negative individuals7. Whether adjunctive dexamethasone 
is more or less likely to be beneficial in HIV-positive individu-
als with TBM is not known. There are an estimated 100,000 
cases of TBM globally each year8, many associated with HIV. 
Clinical trial data are required to provide an evidence base 
for adjunctive dexamethasone in HIV-positive individuals 
with TBM, and to guide clinical practice.
Structure and status of trial
The ACT HIV trial commenced recruitment on 25th May 
2017. By April 29th 2021, the predefined sample size of 520 
adults with TBM and HIV co-infection had been enrolled 
from four hospitals in Vietnam and Indonesia: the Hospital 
for Tropical Diseases (HTD) and Pham Ngoc Thach Hospital 
for Tuberculosis and Lung Disease (PNT) in Ho Chi Minh 
City, Vietnam, and Cipto Mangunkusumo Hospital and Persa-
habatan Hospital in Jakarta, Indonesia. Detailed enrolment cri-
teria for ACT HIV, including consent and ethical approvals, 
are described in the published trial protocol1.
Once enrolled, study participants were randomised to dexam-
ethasone or placebo (a double-blinded allocation), with this 
intervention termed ‘study drug’. Randomisation was stratified 
by TBM MRC severity score and by hospital. Participants 
with MRC grade 1 TBM received a 6-week tapering course 
of study drug, whereas participants with MRC grades 2 
or 3 received an 8-week tapering course of study drug. Study 
drug regimens are shown in Table 1. Participants then under-
went clinical assessments at baseline, at days 3, 7, 10, 14, 21, 
and 30, monthly until month 12, and then 3-monthly until 
24 months. Baseline assessment included blood tests, chest 
X-ray, lumbar puncture, and brain imaging.
ACT HIV has numerous sub-studies, as described in the 
protocol1. Key follow up outcomes include survival, disabil-
ity, and severe adverse events; especially neurological events, 
events requiring corticosteroids, HIV-associated complica-
tions (malignancies, immune reconstitution inflammatory 




The primary endpoint of the ACT HIV trial is death (from 
any cause) over the first 12 months after randomisation.
Secondary endpoints
The secondary endpoints of the ACT HIV trial are as follows:
1. Neurological disability at 12 months from randomisation
2. First new neurological event or death over the first 12 months 
after randomisation
Table 1. Study drug treatment regimen following 
randomisation.
MRC Grade I 
Daily dexamethasone 
dose/route
MRC Grades II and III 
Daily dexamethasone 
dose/route
Week 1 0.3 mg/kg/24 hrs IV 0.4 mg/kg/24 hrs IV
Week 2 0.2 mg/kg/24 hrs IV 0.3 mg/kg/24 hrs IV
Week 3 0.1 mg/kg/24 hrs IV 0.2 mg/kg/24 hrs IV
Week 4 3mg/24 hrs oral 0.1 mg/kg/24 hrs IV
Week 5 2mg/24 hrs oral 4 mg/24 hrs oral
Week 6 1 mg/24 hrs oral 3 mg/24 hrs oral
Week 7 Stop 2 mg/24 hrs oral
Week 8 1 mg/24 hrs oral
IV=intravenous. MRC=Modified Research Council.
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3. Neurological IRIS events over the first 6 months after 
randomisation
4. New AIDS-defining event or death over the first 12 months 
after randomisation
5. HIV-associated malignancy by 12 months from randomisation
6. Use of open-label corticosteroid treatment for any reason 
over the first 12 months after randomisation
7. Requirement for shunt surgery by 12 months
8. Any serious adverse events reported by 12 months from 
randomisation
Individuals included in analysis
Primary analysis
The primary analysis includes all randomised participants. As 
such, an intention-to-treat (ITT) analysis will be performed 
for the primary and secondary endpoints. Participants will remain 
included in this analysis even if no study drug was received 
after randomisation.
Per protocol analysis
The per protocol (PP) analysis includes all randomised 
patients with the exception of those with a final diagno-
sis other than TBM (confirmed by microbiology, serology, or 
histopathology), and those who received less than 7 days of 
administration of the randomised study drug for reasons other 
than death, or less than 30 days of anti-tuberculosis drugs for 
any reason other than death. A per protocol analysis will be 
performed for all primary and secondary endpoints.
Statistical software
Data will be analysed using the program R9, using the most 
up to date version available at the time of final analysis.
Baseline characteristics
Definition: The following baseline characteristics will be sum-
marised by treatment arm for ITT and PP analyses: age, 
sex, country, site, diagnostic category (definite, probable, pos-
sible, or not TBM by Marais criteria10), history of previous 
tuberculosis treatment, chest X-ray findings (no TB/miliary 
TB/pulmonary TB), enrolment MRC TBM grade, enrolment 
Glasgow coma score (GCS), weight (kg), duration of symptoms, 
cranial nerve palsy, hemiplegia, para/tetraplegia, urinary reten-
tion, history of diabetes, HbA1c, history of intravenous drug 
use, hepatitis B sAg positivity, hepatitis C Ab positivity, alanine 
aminotransferase (ALT), bilirubin, full blood count (haemo-
globin, white cell count, platelets), plasma sodium, leukot-
riene A4 hydrolase (LTA4H) genotype (CC/CT/TT), routine 
CSF parameters (opening pressure, total leucocytes, total neu-
trophils, total lymphocytes, protein, blood:CSF glucose ratio, 
Ziehl-Neelsen stain, Gene Xpert MTB/RIF, Gene Xpert 
MTB/RIF Ultra, mycobacterial culture), duration of anti-
tuberculosis chemotherapy (days) before enrolment, enrol-
ment anti-TB regimen, anti-TB drug susceptibility results in 
culture-confirmed sub-group (multi-drug resistant [MDR] TB 
or rifampicin mono-resistant TB, isoniazid resistant non-MDR, 
pre-extensively drug resistant [XDR] TB, XDR TB, no or other 
resistance), HIV infection (new or known diagnosis), anti- 
retroviral therapy (ART) treatment at enrolment (ART naïve, ≤3 
months of ART, >3 months of ART) and time to starting ART (if 
ART naïve), enrolment CD4 count (median values and categories 
[<50, 51–100, 101–200, >200]), HIV viral load. These will be 
described in a baseline variable table (Table 2).
Analysis: Baseline characteristics will be summarised as 
median (lower and upper quartiles) for continuous data and fre-
quency (percentage) for categorical data. The amount of missing 
data for each baseline characteristic will also be displayed. 
We will perform multiple imputation of a variable in case of 
>5% missing values, and it is assumed that data are missing at 
random. Otherwise, a complete case analysis will be performed.
Use of the uniform case definition diagnostic score
The published TBM diagnostic score10 will be used and sub-
jects will be categorised as ‘definite’, ‘probable’, ‘possible’, or 
‘not TBM’. Participants will only be categorised as ‘not TBM’ 
if they have a confirmed alternative diagnosis (alternative to 
TBM) or they recovered without TB drugs.
Primary endpoint
The primary endpoint of this trial is death over the first 12 
months after randomisation. The primary analysis is a Cox 
proportional hazards regression model with treatment as the 
only covariate. Since TBM MRC severity grade at enrolment 
(I, II, or III) is an important risk factor for mortality and was 
used as stratification variable in the randomisation, we will 
additionally perform a secondary analysis with MRC grade 
added as stratum variable. The proportional hazards assump-
tion will be formally tested based on scaled Schoenfeld residu-
als and visually assessed by a plot of the scaled Schoenfeld 
residuals versus transformed time. Deaths, by study drug arm, 
and the results of the analyses will be shown as per Table 3 and 
Table 4. 
Survivors known to be alive at 12 months will be censored at 
that time-point and subjects who withdrew or were lost to fol-
low-up before 12 months will be censored at the date they 
were last known to be alive. Subjects who withdrew or 
were lost to follow-up before 12 months are estimated to be 
less than 5% of enrolled participants.
The homogeneity of the treatment effect on overall survival 
across subgroups will be assessed by formal tests of interac-
tion between treatment and the following pre-defined grouping 
variables: TBM MRC severity grade at enrolment (I, II, or 
III), diagnostic category (definite, probable, possible), LTA4H 
genotype (CC/CT/TT), drug resistance pattern (MDR TB or 
rifampicin mono-resistant TB, isoniazid resistant non-MDR, 
no or other resistance), ART status at enrolment (ART naïve, 
≤3 months of ART, >3 months of ART), and CD4 cell count 
at enrolment (<50, 51–100, 101–200, >200). We will estimate 
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Age (years) XX XX (XX,XX) XX XX (XX,XX)
Sex - male XX XX (XX%) XX XX (XX%)



























- Definite TBM 
- Probable TBM 






















Previous tuberculosis treatment XX XX (XX%) XX XX (XX%)
Chest X-ray findings 
- No tuberculosis 


















Modified MRC grade 
- Grade I 


















Glasgow coma score XX XX (XX,XX) XX XX (XX,XX)
Weight (kg) XX XX (XX,XX) XX XX (XX,XX)
Duration of symptoms (days) XX XX (XX,XX) XX XX (XX,XX)
Neurological signs 
























History of diabetes XX XX (XX%) XX XX (XX%)
HbA1c (%) XX XX (XX,XX) XX XX (XX,XX)
History of intravenous drug use XX XX (XX%) XX XX (XX%)
Hepatitis B sAg positivity, XX XX (XX%) XX XX (XX%)
Hepatitis C Ab positivity XX XX (XX%) XX XX (XX%)
Alanine aminotransferase (ALT) (IU/L) XX XX (XX,XX) XX XX (XX,XX)
Bilirubin (µmol/L) XX XX (XX,XX) XX XX (XX,XX)
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Full blood count 
- Haemoglobin (g/dL) 
- White cell count (x103/ µL) 







































- Opening pressure (cmH20) 
- Total leucocytes (cells/mm3) 
- Total neutrophils (cells/mm3) 
- Total lymphocytes (cells/mm3) 






























CSF microbiological tests 
- Positive ZN stain 
- Positive GeneXpert MTB/RIF 
- Positive GeneXpert MTB/RIF Ultra 





















Duration of anti-tuberculosis chemotherapy before 
enrolment (days)
XX XX (XX,XX) XX XX (XX,XX)






























Anti-tuberculosis drug resistance* 
- Multi-drug resistant or rifampicin mono-resistant 
- Isoniazid resistant non-MDR 
- Pre-XDR 
- XDR 

























HIV infection: new diagnosis or known positive status XX XX (XX%) XX XX (XX%)
ART status at enrolment 
- ART naïve 
- ≤3 months of ART 



























Time to starting ART# XX XX (XX,XX) XX XX (XX,XX)
Enrolment CD4 count (per mm3) XX XX (XX,XX) XX XX (XX,XX)
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and report the treatment effect by fitting a separate Cox model 
per subgroup. We will additionally fit a Cox model that includes 
CD4 count at enrollment as a continuous variable via a restricted 
cubic spline with four knots and an interaction term with 
treatment arm.
Kaplan-Meier plots and explicit survival estimates at 3, 6, 
and 12 months of follow-up will be calculated for the full sam-
ple and in the subgroups defined above. We will compare the 
treatment arms via the absolute risk of death at 12 months 
(using a Wald-type test based on Kaplan-Meier estimates at 
12 months and associated standard errors using Greenwood’s 
formula) and the restricted mean survival until 12 months 
(using the survRM212 package in R).
Secondary endpoints
Secondary outcomes 2 to 7 below are time-to-event outcomes. 
For each, we will compute and plot the Kaplan-Meier estimates 
(outcomes 2, 4) or the competing risks Aalen-Johansen esti-
mates (outcomes 3, 5, 6 and 7) and report the values of the 
Table 3. Hazard ratio for death (from any cause) over the first 12 months after randomisation.
No. of deaths Hazard ratio 





Corrected for modified MRC grade 




The primary endpoint will be overall survival, i.e., time from randomisation to death, over the first 12 months of follow-up. 
This table reports the results from the Cox proportional hazards regression model. The primary effect measure will be the 
resulting hazard ratio comparing dexamethasone vs. placebo with a corresponding two-sided 95% confidence interval. In 
“All patients”, treatment will be the only covariate. We will additionally report the hazard ratio if the modified MRC grade is 



































HIV viral load (copies/mL) XX XX (XX,XX) XX XX (XX,XX)
*Results given for sub-group with positive mycobacterial culture on baseline CSF. Pre-XDR and XDR are 
defined following World Health Organisation definitions11. #Results given for sub-group naïve to ART at 
enrolment.
N = number of patients included in that statistic. Summary statistic = the median (1st and 3rd quartile) value 
for continuous data, and the number and frequency (%) of patients with the characteristic for categorical 
data.
Definite TBM = positive acid fast bacilli (AFB) on CSF Ziehl Neelsen stain, or positive CSF TB GeneXpert test, 
OR positive CSF TB culture. Probable or possible TBM defined following uniform case defintion10. Confirmed 
non-TBM = microbiologically confirmed other brain infection. Confirmed additional brain infection includes 
positive CSF India Ink stain, OR CSF cryptococcal antigen, OR positive blood cryptococcal antigen, OR positive 
CSF bacterial Gram stain, OR positive CSF bacterial culture, OR positive CSF viral or helminth PCR test.
ART status of a patient will be unknown if i) they are on ART treatment and the start ART date is missing 
completely; or ii) their ART status is unknown. ART status of a patient will be undetermined if start ART date 
is present but distinction between ≤3 months of ART, and >3 months of ART, cannot be made due to limited 
date information.
ART=antiretroviral therapy. HTD=Hospital for Tropical Diseases. MRC=Modified Research Council. PNT=Pham 
Ngoc Thach Hospital for Tuberculosis and Lung Disease. TBM=tuberculous meningitis. XDR=Extensively drug 
resistant. Xpert=Gene Xpert MTB/RIF. ZN=Ziehl Neelsen.
Page 7 of 16
Wellcome Open Research 2021, 6:280 Last updated: 15 NOV 2021
estimates at 3, 6 and 12 months. We will also fit a Cox proportional 
hazards model (results are interpreted as relative cause-specific 
hazards in the presence of competing risks). Analyses will 
be performed for the full samples (ITT and PP). Subgroup 
analyses are specified below per secondary endpoint. For the 
subgroup analyses, we follow the same procedure as for the 
primary outcome: we fit separate models per subgroup and 
we fit a model in which we test for interaction by subgroup.
1. Neurological disability at 12 months from 
randomisation
Neurological disability will be assessed by the modified 
Rankin score at months 1, 2, 3, 6, 9, and 12 from randomisation 
(Table 5). The main secondary endpoint is the 12-month assess-
ment and subjects who died before 12 months will be treated 
as having a score of 6 (‘dead’). Rankin score assessments 
will be included from clinical assessments performed monthly 
Table 4. Hazard ratios for death (from any cause) by sub-group over the first 12 months after randomisation.
No. of deaths Hazard ratio  







Modified MRC grade: 
- Grade I 











X.XX (X.XX, X.XX) 









- Definite TBM 
- Probable TBM 













X.XX (X.XX, X.XX) 
X.XX (X.XX, X.XX) 






















X.XX (X.XX, X.XX) 








Anti-tuberculosis drug resistance# 
-  Multi-drug resistant or rifampicin 
mono-resistant
- Isoniazid resistant non-MDR 
- Pre-XDR 
- XDR 



























ART status at enrolment 
- ART naïve 
- ≤3 months of ART 










X.XX (X.XX, X.XX) 
























X.XX (X.XX, X.XX) 
X.XX (X.XX, X.XX) 









*Heterogeneity will be tested with a Cox regression model that includes an interaction between treatment effect and subgroup. #Results will 
be given for sub-group with positive mycobacterial culture on baseline CSF. Pre-XDR and XDR are defined following World Health Organisation 
definitions11.
The primary endpoint will be overall survival, i.e., time from randomisation to death, over the first 12 months of follow-up. This table reports 
the results from the Cox proportional hazards regression model. The primary effect measure will be the resulting hazard ratio comparing 
dexamethasone vs. placebo with a corresponding two-sided 95% confidence interval.
In these subgroup analyses, a separate Cox model will be fitted for each value of the subgroup. The “Test for heterogeneity” will be based on 
the likelihood ratio test that includes subgroup as covariate and compares the models with subgroup as main effect only and with subgroup as 
treatment effect modifier, with TBM MRC severity grade at enrolment (I, II, or III) as covariates.
ART=antiretroviral therapy. MRC=Modified Research Council. TBM=tuberculous meningitis. XDR=extensively drug resistant.
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(+/- 7 days), with the exception of the 12-month clinical assess-
ment for which an acceptable range of -10 days/+1 month 
will be applied. All clinical assessment timings are based on 
days from randomisation (i.e., ‘day 0’ is labeled as the first day 
study drug is received, with study drug received immediately 
after randomisation).
Neurological disability (as assessed by the ordinal modified 
Rankin scale) at 12 months will be compared between the two 
arms with a proportional odds logistic regression model with 
the treatment assignment as the main covariate and adjust-
ment for TBM MRC severity grade. The result will be sum-
marised as a cumulative odds ratio with corresponding 95% 
confidence interval and p‐value. Individuals who withdrew 
or were lost to follow-up before 12 months are excluded.
2. First new neurological event or death over the first 12 
months after randomisation
A new neurological event is defined as a fall in GCS by 
≥2 points for ≥2 days from the highest previously recorded 
GCS (including baseline) or the onset of any of the follow-
ing clinical adverse events: cerebellar symptoms, focal neuro-
logical signs, or onset of seizures. A description of all the events 
will be given, summarising how they met the criteria.
Analyses will additionally be performed in the subgroups 
defined by TBM MRC severity grade, diagnostic category, 
ART status at enrolment, time from randomisation to start of 
ART, and baseline CD4 count.
3. First IRIS event over the first 6 months after 
randomisation
The criteria for neurological IRIS diagnosis is defined in the 
study protocol1. The neurological IRIS rate will be defined as 
the number of IRIS events divided by the observed person-time 
of follow-up in each treatment group. A description of all 
the IRIS events will be given, describing how they met the 
IRIS diagnostic criteria.
The number of IRIS events in each group will be summarised. 
Death will be interpreted as a competing risk. Analyses will 
additionally be performed in the subgroups defined by TBM 
MRC grade, diagnostic category, ART status at enrolment, 
time from randomisation to start of ART, and baseline CD4 
count.
4. AIDS-defining event or death over the first 12 months 
after randomisation
Acquired immunodeficiency syndrome (AIDS)-defining ill-
nesses will be defined as per the World Health Organisation 
(WHO) classification. WHO define AIDS as a clinical diagnosis 
(presumptive or definitive) of any stage 4 HIV condition13.
5. HIV-associated malignancy over the first 12 months 
after randomisation
HIV-associated malignancy is defined as new diagnosis of 
one or more of the three major HIV-associated malignancies; 
Kaposi sarcoma, high grade B-cell non-Hodgkin lymphoma or 
invasive cervical cancer.
The number of HIV-associated malignancy events in each 
group will be summarised. Death will be interpreted as a com-
peting risk. Analyses will additionally be performed in the 
subgroups defined by ART status at enrolment.
6. Use of open-label corticosteroid treatment for any 
reason, and at any time, after randomisation
The number of open-label corticosteroid treatment events in 
each group will be summarised. The reasons for corticoster-
oid treatment will be listed. Death will be interpreted as a 
competing risk.
7. Requirement for shunt surgery by 12 months
The number of shunts performed in each group will be 
summarised. Death will be interpreted as a competing risk.
Adverse events until 12 months
Serious adverse events (SAE) are defined in the study 
protocol1. SAE will be sub-grouped into categories. SAE will 
be grouped and graded as per Common Terminology Criteria 
for Adverse Events (CTCAE)14.
Table 5. The Modified Rankin Scale.
Score Description
0 No symptoms
1 Minor symptoms not interfering with lifestyle
2 Symptoms that lead to some restriction in lifestyle, but do not interfere with the patients ability to look after themselves
3 Symptoms that restrict lifestyle and prevent totally independent living
4 Symptoms that clearly prevent independent living, although the patient does not need constant care and attention.
5 Totally dependent, requiring constant help day and night.
6 Death
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The number of patients with any serious adverse event will be 
summarised and compared between the two treatment arms 
based on the chi-squared test, or Fisher’s exact test in case the 
expected count under the null hypothesis in at least one of 
the cells is smaller than one15. Specific adverse events will be 
summarised, but not formally compared. The total number of 
serious adverse event episodes per patient will also be sum-
marised and informally compared based on a quasi-Poisson 
regression model with treatment as the only covariate.
The following subgroups of adverse events will also be sepa-
rately summarised: clinical grade 3&4 adverse events; serious 
adverse events possibly, probably, or definitely related to 
the study drug; adverse events leading to TB treatment or 
ARV interruptions. Grade 3&4 laboratory abnormalities will 
be summarised in the same way as clinical adverse events. 
Adverse events will be shown as per Table 6–Table10.
Explanatory analysis via multivariate model
A multivariate model of variables independently associated 
with death will include: age, enrolment GCS, TBM diagnos-
tic category (definite, probable, possible), study drug allocation 
(dexamethasone vs. placebo), CD4 count, CSF total leuco-
cytes, CSF total neutrophils, CSF blood:glucose ratio, CSF 







N.pt N.ae N.pt N.ae  
Any selected serious adverse event XX (XX%) XX XX (XX%) XX X.XX
Serious adverse events of all types XX (XX%) XX XX (XX%) XX X.XX
N.pt = the number of patients with at least one serious adverse event (% of all patients receiving the same 
intervention)
N.ae = the total number of episodes of that particular serious adverse event






















Important medical event 
which may jeopardise 



















Name of event XX (XX%) XX (XX%) XX (XX%) XX (XX%) XX (XX%) XX (XX%)
* Subjects were at immediate risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe
** A substantial disruption of a person’s ability to conduct normal life functions
N is the number of all patients, n is the number of patients with a non-missing value
Summary statistic is absolute count (%) for categorical variable(s).







N.pt N.ae N.pt N.ae  
Any selected serious adverse event possibly, probably, 
or definitely related to the study drug
XX (XX%) XX XX (XX%) XX X.XX
Serious adverse events of all types possibly, probably, 
or definitely related to the study drug
XX (XX%) XX XX (XX%) XX X.XX
N.pt = the number of patients with at least one serious adverse event (% of all patients receiving the same intervention)
N.ae = the total number of episodes of that particular serious adverse event
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lactate. Numeric variables will be analysed using restricted 
cubic splines. We will not include any interactions.
Data availability
No data is associated with this article.
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N.pt N.ae N.pt N.ae  
Any selected clinical grade 3&4 adverse event XX (XX%) XX XX (XX%) XX X.XX
Clinical grade 3 adverse events of all types XX (XX%) XX XX (XX%) XX X.XX
Clinical grade 4 adverse events of all types XX (XX%) XX XX (XX%) XX X.XX
Clinical grade 3&4 adverse events of all types XX (XX%) XX XX (XX%) XX X.XX
N.pt = the number of patients with at least one adverse event (% of all patients receiving the same intervention)
N.ae = the total number of episodes of that particular adverse event
The ‘clinical grade 3&4 adverse events of all types’ grouping will include only the group of adverse events that cannot 
be separated into grades 3 or 4 (recorded as ‘grade 3 or 4’ at the beginning of the trial). These events will not also be 
represented in the above ‘grade 3’ and ‘grade 4’ rows.







N.pt N.ae N.pt N.ae  
Any selected adverse event leading to TB treatment or antiretroviral interruptions XX (XX%) XX XX (XX%) XX X.XX
Adverse events of all types leading to TB treatment or antiretroviral interruptions XX (XX%) XX XX (XX%) XX X.XX
N.pt = the number of patients with at least one serious adverse event (% of all patients receiving the same intervention)
N.ae = the total number of episodes of that particular serious adverse event







N.pt N.ae N.pt N.ae  
Any selected grade 3&4 laboratory abnormalities XX (XX%) XX XX (XX%) XX X.XX
Grade 3&4 laboratory abnormalities of all types XX (XX%) XX XX (XX%) XX X.XX
N.pt = the number of patients with at least one serious adverse event (% of all patients receiving the same intervention)
N.ae = the total number of episodes of that particular serious adverse event
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Box 1. ACT HIV study group (listed by group, and then alphabetically).
Pham Ngoc Thach Hospital for Tuberculosis and Lung Disease, Ho Chi Minh City, 
Vietnam
Dr Truong Thi Anh 
Dr Nguyen Duc Bang 
Dr Luu Tuan Bang 
Pham Thi Anh Dao 
Dr Nguyen Thuong Dat 
Do Kim Dung 
Dr Le Tien Dung
Dr Dang Minh Duong 
Dr Do Chau Giang 
Dr Dang Thi Minh Ha 
Dr Nguyen Thi Thu Hiep 
Dr Nguyen Huu Lan 
Dr Nguyen Huu Minh 
Dr Huynh Phat
Dr Dang Van Thanh 
Vo Thi Thanh Thuy 
Dr Nghiem Huyen Trang 
Dr Nguyen Nang Vien
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Dr Le Thi My Chau 
Dr Nguyen Van Vinh Chau 
Nguyen Thi Ha 
Dr Nguyen Ho Hong Hanh 
Dr Tran Minh Luan 
Dr Ho Dang Trung Nghia 
Dr Pham Kieu Nguyet Oanh 
Dr Nguyen Hoan Phu
Dr Van Thi Xuan Quynh 
Dr Nguyen Truc Thanh
Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
Professor Guy E. Thwaites 
Biostatistics group 
Dr Ronald B. Geskus 
Dr Dong Huu Khanh Trinh 
Dr Le Thi Phuong Thao 
Clinical trials unit 
Dr Nguyen Thi Phuong Dung 
Dau Thi Thanh Huong 
Evelyne Kestelyn
Lam Hong Bao Ngoc 
Nguyen Thi Thao Nguyen 
Trinh Khanh Phuong 
Dr Nguyen Than Ha Quyen 
Nguyen Bao Tran 
Nguyen Thi Huyen Trang 
Dr Celine Vidaillac 
Tuberculosis group 
Tran Dinh Dinh
Dr Joseph Donovan 
Vu Thi Mong Dung 
Vu Thi Ngoc Ha 
Pham Thi Kim 
Nguyen Le Quang 
Do Dang Anh Thu 
Dr Nguyen Thuy Thuong 
Thuong 
Dr Trinh Thi Bich Tram
Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Dr Putri Widya Andini 
Dr Riwanti Estiasari 
Dr Cakra Parindra Gasmara
Dr Ardiana Kusumaningrum 
Dr Darma Imran 
Dr Kartika Maharani
Dr David Pangeran 
Dr Maria Gabriella Sainlia
Persahabatan Hospital, Jakarta, Indonesia
Dr Erlina Burhan 
Dr Teuku Reyhan Gamal
Dr Ihsan Hamdani 
Dr Ashwin Marcel Rumawas
Dr Muhammad Fakhri Zahir
Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia
Professor J. Kevin Baird 
Professor Reinout van Crevel 







Anna Laksmi Sri Wardhani
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complicated. With a simpler regimen compliance would be better.
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